Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 25

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 25
---
 is expected to be JPY 144.81, an increase of JPY 76.45, or 111.8%, and Core EPS is expected to be JPY 485, a decrease of JPY 6, or 1.2%.

<div align='center'>13</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

Major assumptions used in preparing the FY2025 Forecast

|                                                                                      |     |                  |          |            |     |                  |          | Billion JPY or percentage |
|                                                                                      |     | FY2024           
 Actual Results   |          |            |     | FY2025           
 Forecast         |          |                           |
| FX rates                                                                             |     | 1 USD = 152 JPY  
 1 Euro = 163 JPY 
 1 RUB = 1.6 JPY  
 1 CNY = 21.1 JPY 
 1 BRL = 27.4 JPY |          |            |     | 1 USD = 150 JPY  
 1 Euro = 160 JPY 
 1 RUB = 1.7 JPY  
 1 CNY = 20.5 JPY 
 1 BRL = 25.9 JPY |          |                           |
| Cost of sales                                                                        |     |                  | -1,580.2 |            |     |                  | -1,540.0 |                           |
| SG&A expenses                                                                        |     |                  | -1,104.8 |            |     |                  | -1,100.0 |                           |
| R&D expenses                                                                         |     |                  |   -730.2 |            |     |                  |   -750.0 |                           |
| Amortization of intangible assets associated with products                           |     |                  |   -548.2 |            |     |                  |   -500.0 |                           |
| Impairment of intangible assets associated with products*2                           |     |                  |    -95.0 |            |     |                  |    -50.0 |                           |
| Other operating income                                                               |     |                  |          |       26.2 |     |                  |          |                      10.0 |
| Other operating expenses*3                                                           |     |                  |   -206.7 |            |